You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Biosimilars Initiatives

Biosimilar biologic drugs, or “biosimilars”, are highly similar copies of reference biologic drugs (the original brand name biologic drug) that have already been sold in Canada. The implementation of biosimilars provides patients access to effective and cost-effective treatment options.

With support from the pan-Canadian Pharmaceutical Alliance (pCPA), we are supporting healthcare systems across Canada to implement biosimilar drugs.

  • The Pan-Canadian Oncology Biosimilars Initiative aimed to ensure appropriate and cost-effective implementation and use of oncology biosimilars.
  • The Biosimilar Implementation Evaluation Framework provides a toolkit to measure and monitor the effects of different biosimilar funding policies and implementation strategies.